Liquidia Technologies
- Company typePublic
- Founded2004
- HeadquartersMorrisville, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Liquidia Technologies firmographics
Firmographics- Name
- Liquidia Technologies
- Legal name
- Liquidia Corporation
- Website
- http://www.liquidia.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Liquidia Technologies industry classification
Industry- Product category
- Pulmonary Hypertension Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
- akta.pro secondary industry
- Inhalers (MDI/DPI/SMI) (HLAHAIAI)
Keywords
Where Liquidia Technologies is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Liquidia Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- YUTREPIA Product Sales: Revenue from direct sales of FDA-approved YUTREPIA (treprostinil) inhalation powder for treatment of PAH and PH-ILD. Product launched June 2025 following FDA approval.
- Treprostinil Injection Promotion: Service revenue from promotion agreement with Sandoz Inc. sharing profits from sale of generic Treprostinil Injection in the United States.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Prescription pharmaceutical product - pricing determined through insurance coverage and patient assistance programs |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Liquidia Technologies product offering
Product offeringCore offering
Liquidia Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutics for rare cardiopulmonary diseases. Its lead commercial product is YUTREPIA (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), delivered via a palm-sized low-resistance device built on the company's proprietary PRINT particle engineering platform. The company also promotes a generic Treprostinil Injection with partner Sandoz and is developing L606, an investigational sustained-release liposomal treprostinil inhalation suspension.
Product overview
Liquidia Corporation is a biopharmaceutical company focused on rare cardiopulmonary diseases, operating a portfolio of commercial and pipeline products. The commercial portfolio includes YUTREPIA™ (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for PAH and PH-ILD launched in June 2025, and Treprostinil Injection, a generic formulation promoted with partner Sandoz. The pipeline includes L606, an investigational extended-release liposomal formulation of treprostinil administered twice-daily via nebulizer, currently in pivotal Phase 3 trials (Re-Spire). All products leverage the company's proprietary PRINT® technology platform for enhanced drug delivery.
Differentiator
Problem solved
Functional benefit
Brands
- YUTREPIA: FDA-approved inhaled dry-powder formulation of treprostinil for treatment of PAH and PH-ILD, delivered through a palm-sized device using PRINT technology
- L606
- Treprostinil Injection
Products and services
- YUTREPIA (treprostinil) Inhalation Powder FDA-approved inhaled dry-powder formulation of treprostinil indicated for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Delivered through a convenient, low-resistance, palm-sized device using Liquidia's proprietary PRINT technology, with particles 1.3 μm in size precisely engineered with a trefoil shape for enhanced deep-lung deposition. For patients with WHO Group 1 PAH and WHO Group 3 PH-ILD and the pulmonologists, PH specialists, and specialty pharmacies who treat them.
- Treprostinil Injection Fully substitutable AP-rated generic formulation of Remodulin (treprostinil) Injection for treatment of pulmonary arterial hypertension (PAH). Liquidia promotes the product in the United States in conjunction with commercial partner Sandoz, Inc., which holds the ANDA with the FDA.
Quantifiable outcome
- Reduced coughing and improved tolerability in PH-ILD patients over 24 weeks of treatment
- +1 more outcomes
Companies that use Liquidia Technologies
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Liquidia Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Liquidia Technologies partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Pharmosa BiopharmcorePartnership to develop L606 (liposomal treprostinil inhalation suspension), an investigational sustained-release formulation of treprostinil administered twice-daily via rapid nebulization with a hand-held portable system for PAH and PH-ILD treatment.
- Sandoz Inc.coreCommercial partnership for Treprostinil Injection promotion in the United States. Sandoz holds the ANDA with the FDA for the generic formulation while Liquidia promotes appropriate use of the product.
Scale indicators11 records
Recent moves7 records
Expansion highlights7 records
Liquidia Technologies competitors and assessment
Company assessmentDirect peers
- United Therapeutics Corporation: Direct competitor and the incumbent in inhaled treprostinil therapy with Tyvaso and Tyvaso DPI for PAH and PH-ILD. Head-to-head competitor to YUTREPIA in the same patient population and same drug class, and also the plaintiff in ongoing patent litigation against Liquidia.
Emerging players
- Gossamer Bio: Late-stage biopharma developing seralutinib (inhaled PDGF/CSF1R/VEGFR inhibitor) for PAH, including the Phase 3 TORREY study. Competes in the same PAH specialty channel and targets the same pulmonologists and PH specialists as YUTREPIA.
- Aerami Therapeutics: Private biotech developing inhaled imatinib (AER-901) for severe pulmonary diseases including PAH. Competes with YUTREPIA for the same PAH specialist audience with a different mechanism and overlapping clinical development timelines.
- Aerovate Therapeutics: Clinical-stage biopharma developing inhaled imatinib (AV-101) for PH-ILD. Same pulmonary hypertension patient focus as YUTREPIA but with a different mechanism (tyrosine kinase inhibitor), competing for the same PH-ILD prescriber mind-share.
- Tenax Therapeutics: Clinical-stage company developing TNX-103 (oral levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Adjacent pulmonary hypertension franchise competing for the same specialist prescribers and clinical-development infrastructure as Liquidia.
Broad incumbents
- Insmed Incorporated: Respiratory-focused biopharma with Arikayce (approved) and brensocatib (Phase 3) in non-CF bronchiectasis and other pulmonary indications. Not a direct competitor in PAH but a broad respiratory player pursuing adjacent specialty pulmonology markets and competing for similar talent and clinical site infrastructure.
- Bayer AG: Markets Adempas (riociguat), the only approved therapy for chronic thromboembolic pulmonary hypertension (CTEPH) and an approved PAH therapy. A broad incumbent in the pulmonary hypertension space competing for prescriber share across multiple PH subtypes.
- Merck & Co. Acquired Acceleron Pharma in 2021 to obtain Winrevair (sotatercept), the first activin signaling inhibitor approved for PAH. Represents a major new mechanism-based competitor that could shift PAH treatment paradigms and indirectly pressure YUTREPIA's market position.
- Johnson & Johnson (Actelion): Acquired Actelion in 2017 to gain the leading oral PAH franchise (Opsumit/macitentan, Tracleer/ bosentan, Uptravi/selexipag). A broad incumbent that competes with YUTREPIA for PAH patient starts and physician attention across multiple lines of therapy.
Others
- Pharmosa Biopharm: Liquidia's co-development partner for L606 (liposomal treprostinil inhalation suspension). Adjacent rather than directly competitive; develops and supplies the liposomal formulation used in Liquidia's Phase 3 Re-Spire study, making it a key enabling partner in Liquidia's pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Liquidia Technologies social profiles
Digital presenceLiquidia Technologies compliance and trust
Trust signalCompliance4 records
Liquidia Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Liquidia Technologies leadership team
Management profileNumber of profiles
Profiles1 record
Liquidia Technologies funding detail
Funding detailFunding overview
Funding rounds21 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Liquidia Technologies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Liquidia Technologies
What does Liquidia Technologies do?
Liquidia Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutics for rare cardiopulmonary diseases. Its lead commercial product is YUTREPIA (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), delivered via a palm-sized low-resistance device built on the company's proprietary PRINT particle engineering platform. The company also promotes a generic Treprostinil Injection with partner Sandoz and is developing L606, an investigational sustained-release liposomal treprostinil inhalation suspension.
Is Liquidia Technologies a public or private company?
Liquidia Technologies is a public company. It is classified as public and is currently operating.
When was Liquidia Technologies founded?
Liquidia Technologies was founded in 2004. It employs 101 to 250 people.
Where is Liquidia Technologies based?
Liquidia Technologies is headquartered in Morrisville, United States, in the North America region.
How does Liquidia Technologies make money?
Two revenue lines are on record. YUTREPIA Product Sales are the primary driver. The others are treprostinil Injection Promotion.
Who are Liquidia Technologies's main competitors?
United Therapeutics Corporation is listed as a direct peer. Emerging players are Gossamer Bio, Aerami Therapeutics, Aerovate Therapeutics and Tenax Therapeutics. Broad incumbents are Insmed Incorporated, Bayer AG, Merck & Co. and Johnson & Johnson (Actelion). Pharmosa Biopharm is listed as an others.
Does Liquidia Technologies have an API?
No public API is recorded for Liquidia Technologies.
What industry is Liquidia Technologies in?
Liquidia Technologies's product category is Pulmonary Hypertension Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAHAIAI, Inhalers (MDI/DPI/SMI). Its NAICS code is 325411 and its SIC code is 2833.